Editing
Kidney Cancer: Diagnosis and Evaluation
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== AUA ==== *'''[https://pubmed.ncbi.nlm.nih.gov/28479239/ 2021 AUA Guidelines on Renal Mass and Localized Renal Cancer]''' *#'''<span style="color:#ff0000">CBC</span>''' *#'''<span style="color:#ff0000">Urinalysis (including assessment of proteinuria)</span>''' *#'''<span style="color:#ff0000">Comprehensive metabolic panel (electrolytes, liver function tests, assessment of GFR)</span>''' ** CBC should be considered prior to any intervention ** Urinalysis with dipstick and microscopic evaluation should be obtained to assess for proteinuria, hematuria, pyuria or signs of other genitourinary maladies. *** Presence of proteinuria is an important prognostic indicator and can be detected by standard urine dipstick. **** Patients with a positive dipstick test (1+ or greater) should undergo confirmation by a quantitative measurement (protein-to-creatinine ratio or albumin-to-creatinine ratio), as part of a focused medical workup for renal dysfunction. *** Microscopic hematuria should also be further assessed to rule out a co-existing urinary tract conditions ** The comprehensive metabolic panel should be reviewed for electrolyte abnormalities and hepatic functional parameters. *** Abnormalities in hepatic function may prompt further workup to exclude co-existing hepatic disease or metastases which may impact management or overall prognosis *** Elevated ALP and/or bone pain should prompt investigation of potential bone metastases ** '''GFR and degree of proteinuria should be used assign CKD stage in patients with a solid or Bosniak 3/4 complex cystic renal mass, as this will influence management''' *** Proper classification of CKD is outlined in the Kidney Disease: Improving Global Outcomes (KDIGO) Guidelines, which takes into account (3): ***# GFR (CKD-EPI GFR equation) ***# Proteinuria ***# Etiology of CKD *** '''<span style="color:#ff0000">Indications for referral to nephrology in a patient with a renal mass (4):</span>''' **# '''<span style="color:#ff0000">Estimated GFR < 45 mL/min/1.73m2</span>''' **# '''<span style="color:#ff0000">Confirmed proteinuria</span>''' **# '''<span style="color:#ff0000">Diabetics with pre-existing CKD</span>''' **# '''<span style="color:#ff0000">When eGFR is expected to be <30 mL/min/1.73m2 after intervention</span>'''
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information